IMR Press / RCM / Volume 6 / Issue 4 / pii/1561344101368-875969792

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Should Angiotensin Receptor Blockers Be Added to Angiotensin-Converting Enzyme Inhibitors in the Treatment of Heart Failure?
Show Less
1 Section of Cardiology, Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC
Rev. Cardiovasc. Med. 2005, 6(4), 206–213;
Published: 30 December 2005
Angiotensin-converting enzyme (ACE) inhibitors have been the cornerstone of treatment of heart failure. Angiotensin receptor blockers (ARBs) remain an attractive alternative in heart failure patients intolerant of ACE inhibitors. The addition of ARBs to ACE inhibitors in the context of stable heart failure may lead to additional clinical benefits. This is in contrast to heart failure complicating acute myocardial infarction, in which it does not offer any therapeutic advantage.
Angiotensin-converting enzyme inhibitors
Angiotensin receptor blockers
Heart failure
Renin-angiotensin system
Back to top